SCHEMBL6079787

SCHEMBL6079787

COC(=O)c1cc(N)c2cccc(N)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 4/20 0.49
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
PKM P14618 1/20 0.48
PARP1 P09874 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HSD17B10 Q99714 2/20 0.44
CFTR P13569 1/20 0.44
PTGER4 P35408 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
ELANE P08246 1/20 0.41
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40
RECQL P46063 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080401 0.88 NQO2 (0.47) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL6080405 0.88 NQO2 (0.47) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL6080286 0.86 NQO2 (0.45) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL6079384 0.84 ALDH1A1 (0.47) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL6080191 0.81 KDM4E (0.45) KDM4EMAPTPARP1TDP1ELANE
SCHEMBL6079893 0.81 NQO2 (0.41) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL1315731 0.80 KDM4E (0.52) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL6079273 0.80 ALDH1A1 (0.42) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL6080010 0.80 KDM4E (0.51) NQO2KDM4EALDH1A1MAPTPKM
SCHEMBL6080487 0.80 ALDH1A1 (0.42) NQO2KDM4EALDH1A1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL NQO2 2/4885KDM4E 1006/4885ALDH1A1 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.